A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

@article{Duffy2008API,
  title={A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.},
  author={Austin Duffy and Jeremy S Kortmansky and Gary K. Schwartz and Marinela Capanu and S Puleio and Bruce I Minsky and Leonard L Saltz and David Paul Kelsen and Eileen M. O'Reilly},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 1},
  pages={86-91}
}
PURPOSE To determine the maximum tolerated dose (MTD) of erlotinib when administered concurrently with twice weekly gemcitabine and radiation therapy (RT) for locally advanced pancreatic cancer, assess the safety and toxicity profile of this combination and secondarily evaluate response, time to tumor progression and overall survival. METHODS Patients with untreated locally advanced pancreas cancer were treated with daily erlotinib in combination with gemcitabine 40 mg/m(2)/30 min twice… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…